1.52

1.30% -0.02

After Hours: 1.53 0.01 +0.66%

Inmune Bio Inc (INMB)

Overview News Price History Option Chain Financials Discussions Forecast

Inmune Bio Inc stock is traded at $1.52, with a volume of 407.94K. It is down -1.30% in the last 24 hours and up +23.58% over the past month. INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.

Previous Close:

$1.54

Open:

$1.54

24h Volume:

407.94K

Relative Volume:

1.02

Market Cap:

$40.41M

Revenue:

$50,000

Net Income/Loss:

$-45.93M

P/E Ratio:

-0.79

EPS:

-1.9241

Net Cash Flow:

$-23.62M

1W Performance:

+14.29%

1M Performance:

+23.58%

6M Performance:

-6.75%

1Y Performance:

-78.68%

1-Day Range:

$1.46

$1.58

1-Week Range:

$1.33

$1.58

52-Week Range:

$1.09

$11.64

Inmune Bio Inc Stock (INMB) Company Profile

Name

Inmune Bio Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

(858) 964-3720

Address

225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA

Employee

Twitter

@INmuneBio

Next Earnings Date

2026-05-07

Latest SEC Filings

INMB's Discussions on Twitter

Compare INMB vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
INMB Inmune Bio Inc	1.52	40.94M	50,000	-45.93M	-23.62M	-1.9241
VRTX Vertex Pharmaceuticals Inc	427.65	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	721.05	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	807.55	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	303.00	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	313.32	33.06B	5.36B	287.73M	924.18M	2.5229

Inmune Bio Inc Stock (INMB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-01-25	Downgrade	BTIG Research	Buy → Neutral
Jul-01-25	Downgrade	Scotiabank	Sector Outperform → Sector Underperform
Jan-28-25	Initiated	Rodman & Renshaw	Buy
Oct-21-24	Initiated	Alliance Global Partners	Buy
Sep-27-24	Initiated	Raymond James	Outperform
Aug-22-24	Initiated	Scotiabank	Sector Outperform
Jun-01-23	Initiated	Robert W. Baird	Outperform
May-24-22	Downgrade	B. Riley Securities	Buy → Neutral
Jul-07-21	Reiterated	Maxim Group	Buy
Apr-21-21	Initiated	B. Riley Securities	Buy
Jan-22-21	Reiterated	Maxim Group	Buy
Sep-01-20	Initiated	BTIG Research	Buy
Jul-15-20	Reiterated	H.C. Wainwright	Buy

View All

Inmune Bio Inc Stock (INMB) Latest News

04:04 AM

INmune Bio expands collaboration with Anthony Nolan charity By Investing.com - Investing.com Australia

04:04 AM

May 05, 2026

INmune Bio expands collaboration with Anthony Nolan charity - Investing.com UK

May 05, 2026

INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th - 富途牛牛

May 05, 2026

INmune Bio Expands Cord Tissue License for CORDStrom Platform - TipRanks

May 05, 2026

INmune Bio (NASDAQ: INMB) deepens Anthony Nolan CORDStrom supply pact - Stock Titan

May 05, 2026

INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases - The Manila Times

May 05, 2026

Stem cell supply deal broadens CORDStrom push into rare skin disease, cancer - Stock Titan

May 05, 2026

MSN Money - MSN

May 05, 2026

A new biotech coalition says the U.S. needs a national innovation plan - Stock Titan

May 05, 2026

May 03, 2026

INMB INmune Bio delivers narrower than expected Q4 2025 loss, shares rise 5.59 percent in today’s trading session.Community Watchlist - Newser

May 03, 2026

May 01, 2026

INmune Bio (INMB.US) is scheduled to release its earnings report after the market close on May 7. - Moomoo

May 01, 2026

Apr 30, 2026

INmune Bio plans May 7 webcast to discuss Q1 results, update - Stock Titan

Apr 30, 2026

Apr 29, 2026

Quant snapshot: J. Jill, AngioDynamics leads strong buys as INmune Bio, Terrestrial Energy lag - MSN

Apr 29, 2026

INMB stock rises pre-market – what did the FDA say about its Alzheimer’s trial? - MSN

Apr 29, 2026

Apr 27, 2026

INmune Bio (INMB) price target increased by 33.33% to 7.14 - MSN

Apr 27, 2026

Apr 23, 2026

Expanded equity plan and board elections on deck at INmune Bio (NASDAQ: INMB) 2026 meeting - Stock Titan

Apr 23, 2026

Apr 21, 2026

INMB 260515 1.00P (INMB260515P1000) Stock Options Chain | Quotes & News - Moomoo

Apr 21, 2026

Apr 20, 2026

What is the sentiment on INmune Bio (INMB) stock today (Institutional Selling) 2026-04-20Strong Buy Rating - Cổng thông tin điện tử tỉnh Lào Cai

Apr 20, 2026

Apr 17, 2026